Used primarily in the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, this compound acts as a selective serotonin inverse agonist, specifically targeting 5-HT2A receptors. It is beneficial because it does not worsen motor symptoms, which is a common issue with traditional antipsychotics in Parkinson’s patients. It has also been investigated for use in other psychotic disorders, dementia-related psychosis, and schizophrenia, particularly where serotonin pathways are involved. Due to its unique mechanism and favorable side effect profile regarding motor function, it offers a valuable option for patients who are sensitive to movement-related side effects.